Publications by authors named "J Vargaftig"
Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes.
Nephrol Dial Transplant
November 2024
Background: Carfilzomib, a new proteasome inhibitor indicated for patients with relapsed/refractory myeloma, has been associated with cases of thrombotic microangiopathy (CFZ-TMA). The role of variants in the complement alternative pathway and therapeutic potential of complement blockade with eculizumab remain to be determined.
Methods: We report 37 cases of CFZ-TMA recorded in the French reference center for TMA with their clinical characteristics, genetic analysis and outcome according to treatments.
Article Synopsis
- Extranodal NK/T-cell lymphoma, nasal type is a rare and aggressive cancer with a traditionally poor outlook, but a study explored a new treatment combining MGAD chemotherapy with targeted radiotherapy.
- In this study of 35 newly diagnosed patients, 91% achieved complete remission, with promising long-term survival rates of 71% at 2 years and 53% at 5 years.
- While some patients faced manageable side effects and a third relapsed within about 14.5 months, the short treatment approach showed effectiveness and tolerability for this challenging condition.
Article Synopsis
- The study analyzed the incidence and characteristics of therapy-related myeloid neoplasms (t-MN) in ovarian cancer patients treated with PARP inhibitors (PARPi) at a French cancer center.
- Out of 373 patients with ovarian cancer under PARPi treatment, 3.5% developed t-MN, showing longer treatment duration and more severe cytopenias compared to those without t-MN.
- Key findings indicated a high frequency of BRCA1/2 mutations in t-MN patients exposed to PARPi, and the presence of complex karyotypes linked to poor overall survival, highlighting the need for early detection of this complication.